Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

ICCM - IceCure Medical Ltd Последние новости | Finranks

Home

/

ICCM

I

IceCure Medical Ltd (ICCM)

NCM – Цена в реальном времени. Валюта: USD

3.16

-0.35 (-9.97%)

Рынок открыт: Aug 12, 2026, 2:01 PM EDT

3.53

+0.02 (0.57%)

Предыдущая сессия: Aug 11, 2026, 7:14 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position CAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial and operational results as of and for the six months ended June 30, 2026.

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval The site will be led by breast surgeon, Dr. Dennis Holmes, MD, FACS, a recognized leader in breast cancer cryoablation CAESAREA, Israel, August 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that Adventist Health Glendale in Glendale, California has signed an agreement and received approval from the Institutional Review Board to become the first clinical site able to enroll patients for the Company's post-marketing "ChoICE ," study (the "ChoICE Study"), for ProSense® in the local treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025.

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

CAESAREA, Israel, Aug. 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2026 before the Nasdaq Stock Market opens on Wednesday, August 12, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position CAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial and operational results as of and for the six months ended June 30, 2026.

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval The site will be led by breast surgeon, Dr. Dennis Holmes, MD, FACS, a recognized leader in breast cancer cryoablation CAESAREA, Israel, August 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that Adventist Health Glendale in Glendale, California has signed an agreement and received approval from the Institutional Review Board to become the first clinical site able to enroll patients for the Company's post-marketing "ChoICE ," study (the "ChoICE Study"), for ProSense® in the local treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025.